BACKGROUND: Overexpression of the tumor suppressor gene melanoma differentiation-associated gene-7 (mda-7) induces apoptosis in many cancer cells, and adenoviral-mediated overexpression of mda-7 downregulates beta-catenin and PI 3-kinase signaling in breast cancer cells. Trastuzumab (Herceptin) improves the efficacy of chemotherapeutics against Her-2/neu-overexpressing breast cancer cells. We sought to evaluate the impact of combination therapy of a recombinant adenovirus vector encoding for human mda-7 (Ad-mda7) and Herceptin on Her-2/neu-overexpressing breast cancer. METHODS: The MCF-7-Her-18 cell line was subjected to treatment with Ad-mda7 with and without Herceptin. Western blot analysis was performed with antibodies to beta-catenin, Akt, and phosphorylated Akt (p-Akt). The same treatment groups were utilized in a nude mouse model in vivo. Treatment was initiated when the tumors reached 100 mm3 in size. RESULTS: In Western blotting, the combination of Ad-mda7 + Herceptin showed decreased levels of beta-catenin, Akt and p-Akt compared with Ad-mda7 or Herceptin alone (P < .05). The in vivo analysis revealed a marked decrease in tumor size with the Ad-mda7 + Herceptin combination (P < .05). CONCLUSIONS: These studies demonstrate the growth inhibitory effect of Ad-mda7 + Herceptin on Her-2/neu-overexpressing breast cancer cells in vitro and in vivo. This combination appears to inhibit the pathways involving beta-catenin and Akt, which play important roles in the growth of breast cancer cells. Copyright 2004 Elsevier Inc.
BACKGROUND: Overexpression of the tumor suppressor gene melanoma differentiation-associated gene-7 (mda-7) induces apoptosis in many cancer cells, and adenoviral-mediated overexpression of mda-7 downregulates beta-catenin and PI 3-kinase signaling in breast cancer cells. Trastuzumab (Herceptin) improves the efficacy of chemotherapeutics against Her-2/neu-overexpressing breast cancer cells. We sought to evaluate the impact of combination therapy of a recombinant adenovirus vector encoding for humanmda-7 (Ad-mda7) and Herceptin on Her-2/neu-overexpressing breast cancer. METHODS: The MCF-7-Her-18 cell line was subjected to treatment with Ad-mda7 with and without Herceptin. Western blot analysis was performed with antibodies to beta-catenin, Akt, and phosphorylated Akt (p-Akt). The same treatment groups were utilized in a nude mouse model in vivo. Treatment was initiated when the tumors reached 100 mm3 in size. RESULTS: In Western blotting, the combination of Ad-mda7 + Herceptin showed decreased levels of beta-catenin, Akt and p-Akt compared with Ad-mda7 or Herceptin alone (P < .05). The in vivo analysis revealed a marked decrease in tumor size with the Ad-mda7 + Herceptin combination (P < .05). CONCLUSIONS: These studies demonstrate the growth inhibitory effect of Ad-mda7 + Herceptin on Her-2/neu-overexpressing breast cancer cells in vitro and in vivo. This combination appears to inhibit the pathways involving beta-catenin and Akt, which play important roles in the growth of breast cancer cells. Copyright 2004 Elsevier Inc.
Authors: Luni Emdad; Devanand Sarkar; Irina V Lebedeva; Zao-Zhong Su; Pankaj Gupta; Parameshwar J Mahasreshti; Paul Dent; David T Curiel; Paul B Fisher Journal: J Cell Physiol Date: 2006-08 Impact factor: 6.384
Authors: Mitchell E Menezes; Praveen Bhoopathi; Anjan K Pradhan; Luni Emdad; Swadesh K Das; Chunqing Guo; Xiang-Yang Wang; Devanand Sarkar; Paul B Fisher Journal: Adv Cancer Res Date: 2018-03-02 Impact factor: 6.242
Authors: Christopher P Gully; Fanmao Zhang; Jian Chen; James A Yeung; Guermarie Velazquez-Torres; Edward Wang; Sai-Ching Jim Yeung; Mong-Hong Lee Journal: Mol Cancer Date: 2010-02-22 Impact factor: 27.401
Authors: Mitchell E Menezes; Shilpa Bhatia; Praveen Bhoopathi; Swadesh K Das; Luni Emdad; Santanu Dasgupta; Paul Dent; Xiang-Yang Wang; Devanand Sarkar; Paul B Fisher Journal: Adv Exp Med Biol Date: 2014 Impact factor: 2.622
Authors: Sujit K Bhutia; Swadesh K Das; Belal Azab; Mitchell E Menezes; Paul Dent; Xiang-Yang Wang; Devanand Sarkar; Paul B Fisher Journal: Int J Cancer Date: 2013-07-06 Impact factor: 7.396